Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.

[1]  A. Waldo.  Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program , 2007 .

[2]  M. Pfeffer,et al.  Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. , 2006, American heart journal.

[3]  Karl Swedberg,et al.  Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. , 2005, European heart journal.

[4]  M. Lehto,et al.  Cardiovascular Morbidity and Mortality in Hypertensive Patients With a History of Atrial Fibrillation , 2005 .

[5]  M. Nieminen,et al.  Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. , 2005, Journal of the American College of Cardiology.

[6]  Gianni Tognoni,et al.  Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). , 2005, American heart journal.

[7]  M. Nieminen,et al.  Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. , 2005, Journal of the American College of Cardiology.

[8]  S. Solomon,et al.  Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients: The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Program , 2004, Circulation.

[9]  K. Swedberg,et al.  Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. , 2004, European heart journal.

[10]  Ali Ahmed,et al.  Impact of atrial fibrillation on mortality and readmission in older adults hospitalized with heart failure , 2004, European journal of heart failure.

[11]  K. Swedberg,et al.  Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. , 2004, Journal of the American College of Cardiology.

[12]  J. Cleland,et al.  Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? , 2003, Journal of the American College of Cardiology.

[13]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[14]  N. Freemantle,et al.  The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. , 2003, European heart journal.

[15]  J. Murabito,et al.  Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality The Framingham Heart Study , 2003, Circulation.

[16]  H. Krumholz,et al.  Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. , 2003, Journal of the American College of Cardiology.

[17]  B. Brendorp,et al.  Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function. , 2003, European heart journal.

[18]  W. Maisel,et al.  Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. , 2003, The American journal of cardiology.

[19]  J. Steiner,et al.  Gender, age, and heart failure with preserved left ventricular systolic function. , 2003, Journal of the American College of Cardiology.

[20]  James B Seward,et al.  Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. , 2002, Journal of the American College of Cardiology.

[21]  L. Tavazzi,et al.  Clinical features and prognosis associated with a preserved left ventricular systolic function in a large cohort of congestive heart failure outpatients managed by cardiologists. Data from the Italian Network on Congestive Heart Failure. , 2002, Italian heart journal : official journal of the Italian Federation of Cardiology.

[22]  E. Philbin,et al.  Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. , 2000, The American journal of medicine.

[23]  S. Yusuf,et al.  Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. , 2000, Chest.

[24]  I. V. Van Gelder,et al.  Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. , 2000, European heart journal.

[25]  W. Stevenson,et al.  Atrial fibrillation in heart failure. , 1999, The New England journal of medicine.

[26]  M. Pfeffer,et al.  Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. , 1999, Journal of cardiac failure.

[27]  S. Kimmel,et al.  Prognostic significance of atrial fibrillation in patients at a tertiary medical center referred for heart transplantation because of severe heart failure. , 1999, The American journal of cardiology.

[28]  M A Waclawiw,et al.  Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. , 1998, Journal of the American College of Cardiology.

[29]  G. Kay,et al.  Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. , 1997, Journal of the American College of Cardiology.

[30]  F. Morady,et al.  Effect of an irregular ventricular rhythm on cardiac output. , 1996, The American journal of cardiology.

[31]  W. Stevenson,et al.  Improving survival for patients with advanced heart failure: a study of 737 consecutive patients. , 1995, Journal of the American College of Cardiology.

[32]  J. Cohn,et al.  The Influence of Atrial Fibrillation on Prognosis in Mild to Moderate Heart Failure The V‐HeFT Studies , 1993, Circulation.

[33]  W G Stevenson,et al.  Prognostic Significance of Atrial Fibrillation in Advanced Heart Failure: A Study of 390 Patients , 1991, Circulation.